The importance of type I
insulin-like growth factor receptor (IGF-IR) overexpression in mammary
tumorigenesis was recently shown in two separate transgenic models. One of these models, the MTB-IGFIR transgenics, was generated in our lab to overexpress IGF-IR in mammary epithelial cells in a
doxycycline (Dox)-inducible manner. To
complement this transgenic model, primary cells that retained Dox-inducible expression of IGF-IR were isolated from a transgenic mammary
tumor. This cell line, RM11A, expressed high levels of IGF-IR, phosphorylated Akt, and phosphorylated
extracellular signal-regulated kinase 1/2 in the presence of Dox. IGF-IR overexpression provided the primary
tumor cells with a survival advantage in
serum-free media and seemed to induce
ligand-independent activation of the IGF-IR because RM11A cells cultured in the presence of Dox were largely nonresponsive to exogenous IGFs. IGF-IR overexpression also augmented the growth of RM11A cells in vivo because injection of these cells into mammary glands of wild-type mice produced palpable
tumors in 15.8 +/- 3.4 days when the mice were administered Dox, compared with 57.8 +/- 6.3 days in the absence of Dox.
DNA microarray analysis revealed a number of genes regulated by IGF-IR, one of which was
cyclin D1. Suppression of IGF-IR expression in vitro or in vivo was associated with a decrease in
cyclin D1 protein, suggesting that at least some of the proliferative actions of IGF-IR are mediated through
cyclin D1. Therefore, this article characterizes the first primary murine mammary tumor cell line with inducible IGF-IR expression. These cells provide a powerful in vitro/in vivo model to examine the function of IGF-IR in mammary
tumorigenesis.